29 results about "Uveitis" patented technology

Described herein are modified monoterpene TRPM8 activating compounds. In particular, provided herein are compounds that affect intracellular ion channel function, and are useful as or in conjunction with therapeutic agents. The compounds provided herein are useful in the treatment of a variety of diseases and disorders, including inflammatory eye diseases (e.g., uveitis), cardiovascular diseases, inflammatory diseases, and diseases characterized by aberrant hyperplasia (e.g., cancer).

The invention is concerned with a method of predicting response to an IL-6 angatonist such as anti-IL-6 antibody by determing the concentration of IL-6 in human aqueous humor. The invention is also concerned with an IL-6 angatonist for use in treatment of uveitis or uveitic macular edema.

The present invention belongs to the technical field of medicine, and in particular relates to a novel aromatic ring derivative containing an amide substitution or a pharmaceutically acceptable salt thereof. The diseases comprise, but are not limited to, inflammatory or autoimmune diseases such as psoriasis, psoriatic arthritis, dermatitis, lupus erythematosus, inflammatory bowel disease, hidradenitis suppurativa, rheumatoid arthritis, and uveitis. The structure of the compound of formula I is as described in the claims and the description. The aromatic ring derivative containing an amide substitution provided in the present invention is used as a novel TYK2 inhibitor, has a good TYK2 inhibitory effect, has a good therapeutic effect in an in vivo model of psoriasis and asthma animals, and has good druggability, high stability and good safety.

The invention belongs to the technical field of biology, and relates to a construction method of a renal tubular interstitial nephritis-uveitis syndrome mouse model. Comprising the following steps: anesthetizing a mouse; carrying out subcutaneous injection on photoreceptor intercellular vitamin A binding proteins and a complete Freund's adjuvant on the front neck, the thighs on the two sides and the back of the anesthetized mouse, and carrying out active immunization; and performing intraperitoneal injection on the actively immunized mouse by adopting pertussis toxin, and performing final immunization. According to the invention, the renal tubular interstitial nephritis-uveitis syndrome mouse model is successfully constructed, so that a foundation is laid for subsequent pathological mechanism research of the disease, and a support can be provided for further development of medicine research for treating the disease.

The present application provides an acesulfame implant which is stable, safe and can achieve at least 6 months of sustained release, can effectively treat various eye diseases including but not limited to glaucoma, cataract, retinal vein obstruction (RVO), uveitis, diabetic macular edema (DME) and age-related macular degeneration (wAMD and nAMD), etc., avoids repeated administration, reduces the formation of side effects, reduces the cost of drug use, and meets the high stability required by drug preparation in production, storage and transportation, has good application prospect, and meets the unmet clinical needs.

The present invention relates to superoxide dismutase and uses thereof for preventing or treating diabetic retinopathy or uveitis. The superoxide dismutase according to the present invention can be effectively used in the prevention or treatment of diabetic retinopathy or uveitis, particularly through oral administration.

The application discloses application of NAMPT as a target point in preparation of a medicine for treating uveitis, wherein the medicine contains a NAMPT inhibitor, the NAMPT inhibitor is FK866, and the NAMPT inhibitor is used for inhibiting expression or activity of NAMPT, thereby down-regulating CD4 + The Hif1a expression level of T cells reestablishes the Teff / Treg balance, and inhibits occurrence and development of uveitis, thereby providing a brand-new drug target for treatment of uveitis. Meanwhile, the application verifies that the NAMPT-HIF1a axis has conservation and potential treatment value in uveitis through experiments, proves that NAMPT can become a potential treatment target of uveitis, and proposes that a NAMPT inhibitor is used for preparing the medicine for treating uveitis, thereby laying a solid theoretical and experimental foundation for development of a new generation of targeted medicine for treating uveitis.

The invention relates to the technical field of biological medicine, in particular to application of MAGT1 small interfering RNA in preparation of medicine for treating uveitis, the MAGT1 small interfering RNA is RNA for interfering and reducing the expression quantity of MAGT1, the MAGT1 small interfering RNA provided by the invention can efficiently knock down the expression quantity of MAGT1 protein, down-regulate the proportion of Th1 cells and Th17 cells in CD4 + T cells and up-regulate the proportion of Treg cells, and the MAGT1 small interfering RNA can be used for preparing medicine for treating uveitis. According to the present invention, with the application of the pharmaceutical composition, the inflammatory reaction of uveitis is relieved, especially the treatment effect on the Vogt-Salix babylonica original field syndrome is provided, the supplement is provided for the uveitis pathogenesis, and the new strategy is provided for the target treatment of the uveitis.

The invention discloses an application of APOE as a target in preparation of a medicine for preventing and / or treating uveitis, the medicine comprises an APOE inhibitor, and the APOE inhibitor is used for inhibiting expression or activity of APOE protein so as to reduce microglial cell mediated inflammatory response. The invention discloses a key effect of APOE in uveitis pathogenesis, especially in microglial cell activation, for the first time, and provides a brand new drug target for treatment of uveitis; the inhibitor aiming at APOE can intervene in abnormal activation of microglial cells from the source, and possibly has better specificity and fewer side effects than a traditional immunosuppressor; meanwhile, the invention lays a solid theoretical and experimental foundation for developing a new generation of drugs for targeted therapy of uveitis.

The invention belongs to the technical field of biological medicine, and particularly relates to a soluble microneedle patch for in-situ drug delivery of trabecular meshwork tissue and a preparation method and application of the soluble microneedle patch. The soluble microneedle patch comprises a fan-ring-shaped backing and a microneedle array arranged on the fan-ring-shaped backing; the micro-needle and the fan-ring-shaped backing are both prepared from polyvinyl alcohol (PVA), the PVA concentration for preparing the micro-needle and the fan-ring-shaped backing is 5%-25%, and the PVA concentration is obtained by weighing 0.5 g-2. 5 g of PVA powder and dissolving the PVA powder in 10 mL of pure water or PBS. The microneedle patch is suitable for delivery of various types of drugs, is expected to be used for treatment of various eye diseases including glaucoma, ocular hypertension, cataract, uveitis, conjunctivitis, xerophthalmia and the like, and has important clinical application value and commercial value.

The invention discloses application of oroxylum indicum total flavonoids in preparation of a medicine for treating uveitis. Experiments prove that the eye drops taking the oroxylum indicum total flavonoids or the oroxylin A as the active ingredient can reduce the uveitis eye inflammation and retina injury degree and reduce the infiltration quantity of inflammatory cells. The oroxylum indicum general flavone is taken as an oral medicine, so that inflammatory infiltration cells of a vitreous cavity and an iris-ciliary body can be reduced, bleeding symptoms can be effectively improved, hyperplasia of iris-ciliary body tissues can be inhibited, and infiltration of leukocytes of aqueous humor in mouse eyes can be effectively inhibited.

A non-invasive diagnostic system is disclosed that integrates Raman spectroscopy with Artificial Intelligence (AI) to detect, classify, and quantify biomarkers and pharmacologic agents in the aqueous humor of the anterior chamber of the eye. The system includes a handheld or slit lamp-mounted Raman probe, a spectral acquisition and preprocessing pipeline, and an AI analysis engine trained to recognize disease-associated molecular signatures. The platform supports real-time diagnosis of glaucoma, uveitis, and other anterior segment conditions, enabling early detection, risk stratification, and longitudinal monitoring. The AI component is capable of incorporating newly discovered biomarkers and contextual factors such as medication use, diurnal variation, and anatomical sampling location. Diagnostic outputs are presented with confidence scores and may include disease classification, biomarker trends, or pharmacologic exposure levels. Built-in safety protocols ensure ANSI Z136.1-compliant laser use, while explainable AI tools and federated learning enhance transparency and clinical adaptability.

The present invention relates to a method for predicting response to an IL-6 antagonist, such as an anti-IL-6 antibody, by determining the concentration of IL-6 in human aqueous humor. The present invention also relates to an IL-6 antagonist for use in treating uveitis or uveitic macular edema.

The invention discloses an application of PPIF as a target in preparation of a medicine for preventing and / or treating uveitis, the medicine comprises a PPIF inhibitor, and the PPIF inhibitor is used for inhibiting expression or activity of PPIF protein so as to reduce microglial cell mediated inflammatory response. The invention discloses the key effect of PPIF in the uveitis pathogenesis, especially in microglial cell activation, for the first time, and provides a brand new drug target for treatment of uveitis; an inhibitor aiming at PPIF can intervene in abnormal activation of microglial cells from the source, and possibly has better specificity and fewer side effects compared with a traditional immunosuppressor; meanwhile, the invention lays a solid theoretical and experimental foundation for developing a new generation of drugs for targeted therapy of uveitis.

The invention relates to the field of biological medicine, in particular to a BU (Behcet's disease uveitis) biomarker screening method based on an intestinal microorganism metagenome, a screened BU biomarker combination and application of the biomarker combination in BU diagnosis. The kit is especially suitable for early diagnosis of BU and differential diagnosis of other systemic immune diseases. The biomarker combination consists of 24 intestinal strains, and is obtained by analyzing excrement metagenome data of BU patients, other systemic immune disease patients and healthy controls through diversity analysis, LEfSe screening and ROC verification. The marker has high sensitivity and specificity, can effectively distinguish BU from healthy people and diseases such as VKH, AS, RA, CD and UC, is suitable for developing a non-invasive BU diagnostic kit, and remarkably improves the clinical diagnosis efficiency.

The present invention belongs to the field of medicine, and in particular relates to novel aromatic ring derivatives having amide substitutions or pharmaceutically acceptable salts thereof. Diseases include, but are not limited to, inflammatory or autoimmune diseases such as psoriasis, psoriatic arthritis, dermatitis, lupus erythematosus, inflammatory bowel disease, hidradenitis suppurativa, rheumatoid arthritis, and uveitis. The structure of the compound of Formula I is as set forth in the claims and the specification. The aromatic ring derivatives having amide substitutions provided by the present invention can be used as novel TYK2 inhibitors, and have good TYK2 inhibitory activity, good therapeutic effects in in vivo animal models of psoriasis and asthma, and excellent drug discoverability, high stability, and good safety.

The invention relates to the technical field of biological medicines, in particular to nanoparticles as well as a preparation method and application thereof. The invention provides the nano-particles prepared by taking a thiol compound as an antibody carrier material, the permeation efficiency of the antibody in eyes is remarkably improved by the nano-particles through a thiol exchange pathway, and the antibody can reach deep tissues of the eyes through eye drop administration, such as cornea, cornea, cornea and the like. The nano-particle delivery system can be enriched in eye posterior tissues such as retina and choroids, and the nano-particle delivery system shows a good treatment effect in corneal neovascularization eye diseases and uveitis.

This specification describes modified monoterpene TRPM8 activating compounds. In particular, the compounds provided herein affect the function of ion channels in cells and are useful as therapeutic agents or in conjunction with therapeutic agents. The compounds provided herein are useful in the treatment of a variety of diseases and conditions, including inflammatory eye diseases such as uveitis, cardiovascular diseases, inflammatory diseases, and diseases characterized by abnormal growth such as cancer. This specification describes Ca 2+ This is an N-substituted C6 cyclylcarboxamide compound that affects intracellular ion transport, such as ions, and is useful as a therapeutic agent or in combination with one or more additional therapeutic agents.

The invention discloses an exosome protein as a molecular marker for diagnosing uveitis, and belongs to the technical field of molecular diagnos.The molecular marker is isocitrate dehydrogenase 3a (IDH3a) protein in exosomes, and the sequence of the isocitrate dehydrogenase 3a (IDH3a) protein is shown as SEQ ID NO.1. The molecular marker has the advantages of being high in non-invasiveness, high in specificity and sensitivity, easy and convenient to operate, low in cost and the like, early screening can be achieved, and the application prospect is wide. And the method is suitable for popularization and application in clinical laboratories.

The present invention relates to a composition comprising a peptide derived from S- Retinol dehydrogenase (S-antigen, S-Ag). The composition or peptide can be used to prevent and / or inhibit S-Ag autoimmunity, can be used to treat and / or prevent uveitis.

Disclosed are immunomodulatory polypeptides that behave as weak human TLR2 agonists and as potent competitive antagonists of natural pathogenic ligands for TLR2. Also disclosed are compositions comprising such polypeptides, compositions comprising antibodies that specifically bind to such polypeptides, and methods of using the same, including for treating sepsis or reducing the severity or likelihood of occurrence of sepsis, in the treatment of inflammatory or autoimmune diseases including rheumatoid arthritis (RA), in the treatment of atherosclerosis, in the treatment of uveitis, in cancer treatment, in organ transplantation and for reducing graft rejection and promoting fertility. Pharmaceutical compositions and kits, and treatment methods are also disclosed.

The present invention relates to superoxide dismutase and uses thereof for preventing or treating diabetic retinopathy or uveitis. The superoxide dismutase according to the present invention can be effectively used in the prevention or treatment of diabetic retinopathy or uveitis, particularly through oral administration.

This invention relates to the field of image segmentation technology and discloses a method for segmenting uveitis lesions based on a U-shaped encoder-decoder network. First, a multi-branch feature fusion module is constructed as a basic unit, stacked to form a multi-scale feature enhancement encoder. Second, a frequency domain cross-layer feature fusion module is designed in the skip connections, utilizing Haar wavelet decomposition to extract boundary information and combining spatial and channel attention to filter and fuse features. A hybrid Mamba interaction bottleneck module is set at the top of the encoder to align and aggregate multi-level deep features, obtain global context through visual Mamba, and perform mutual correction of global and local features using a joint attention map. In the decoding stage, an uncertainty-aware recursive gating module is introduced, using the Shannon entropy output of the prediction head as the uncertainty map to dynamically modulate the initial gating generated by the gating network, achieving adaptive control of the intensity of shallow detail introduction.

The invention discloses an application of complement C5a in preparation of a medicine for treating ophthalmic diseases, and relates to the technical field of biological medicine, the C5a promotes glutamine metabolism of RPE cells by enhancing expression of SLC38A1, and cell viability, migration and invasion are improved; the up-regulation of the expression of SLC38A1 induced by C5a is promoted by the modification of m6A mediated by METTL3 and HNRNPC. The medicine contains complement C5a organic nanocrystals, is good in safety and tolerance, and has a remarkable curative effect on ophthalmic diseases such as age-related macular degeneration, diabetic retinopathy and uveitis.